JPS5236659A - Racemic and optically active 44*polyalkoxyyphenyl** 22pyrrolidone and neuralgia and mental disease treating agent containing same - Google Patents

Racemic and optically active 44*polyalkoxyyphenyl** 22pyrrolidone and neuralgia and mental disease treating agent containing same

Info

Publication number
JPS5236659A
JPS5236659A JP51111693A JP11169376A JPS5236659A JP S5236659 A JPS5236659 A JP S5236659A JP 51111693 A JP51111693 A JP 51111693A JP 11169376 A JP11169376 A JP 11169376A JP S5236659 A JPS5236659 A JP S5236659A
Authority
JP
Japan
Prior art keywords
polyalkoxyyphenyl
neuralgia
racemic
optically active
agent containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP51111693A
Other languages
English (en)
Japanese (ja)
Other versions
JPS612660B2 (enExample
Inventor
Fuuto Andoreasu
Shiyumiihien Rarufu
Keeru Borufugangu
Paarenshiyaato Deiiteru
Pashieruke Geruto
Buahateru Herumuuto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of JPS5236659A publication Critical patent/JPS5236659A/ja
Publication of JPS612660B2 publication Critical patent/JPS612660B2/ja
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00Compounds having —CHO groups
    • C07C47/52Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18Ethylenedioxybenzenes, not substituted on the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP51111693A 1975-09-18 1976-09-17 Racemic and optically active 44*polyalkoxyyphenyl** 22pyrrolidone and neuralgia and mental disease treating agent containing same Granted JPS5236659A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19752541855 DE2541855A1 (de) 1975-09-18 1975-09-18 4-(polyalkoxy-phenyl)-2-pyrrolidone ii

Publications (2)

Publication Number Publication Date
JPS5236659A true JPS5236659A (en) 1977-03-22
JPS612660B2 JPS612660B2 (enExample) 1986-01-27

Family

ID=5956927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51111693A Granted JPS5236659A (en) 1975-09-18 1976-09-17 Racemic and optically active 44*polyalkoxyyphenyl** 22pyrrolidone and neuralgia and mental disease treating agent containing same

Country Status (18)

Country Link
US (1) US4153713A (enExample)
JP (1) JPS5236659A (enExample)
AT (1) AT349459B (enExample)
BE (1) BE846335R (enExample)
CA (1) CA1077496A (enExample)
CH (1) CH623571A5 (enExample)
CS (1) CS225802B2 (enExample)
DD (1) DD126894A6 (enExample)
DE (1) DE2541855A1 (enExample)
DK (1) DK157919C (enExample)
ES (1) ES451518A2 (enExample)
FR (1) FR2324299A2 (enExample)
GB (1) GB1563398A (enExample)
HU (1) HU173117B (enExample)
IE (1) IE43723B1 (enExample)
NL (1) NL7610300A (enExample)
SE (1) SE407799B (enExample)
SU (1) SU795465A3 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131959B (it) * 1979-08-09 1986-06-25 Hoffmann La Roche Derivati pirrolidinici
US5459145A (en) * 1988-01-19 1995-10-17 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
HU215433B (hu) * 1986-04-29 2000-05-28 Pfizer Inc. Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
AU8292091A (en) * 1990-08-03 1992-03-02 Smithkline Beecham Corporation Tnf inhibitors
DE4032055A1 (de) * 1990-10-05 1992-04-09 Schering Ag Verfahren zur herstellung von optisch aktiven 4-aryl-2-pyrrolidinonen
US5319099A (en) * 1991-01-21 1994-06-07 Shionogi Seiyaku Kabushiki Kaisha 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents
US5514678A (en) * 1992-03-26 1996-05-07 E. I. Du Pont De Nemours And Company Arthropodicidal 1,2,4-triazinyl amides
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
US5395935A (en) * 1992-05-08 1995-03-07 Pfizer Inc. Endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
ATE260911T1 (de) * 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
HUP9702408A3 (en) * 1995-02-10 2000-08-28 Schering Ag Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP2001507349A (ja) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式2−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
MXPA03010810A (es) * 2001-05-29 2004-03-22 Schering Ag Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA709405A (en) * 1965-05-11 Parke, Davis And Company Methods for producing pyrrolidine compounds
US2975193A (en) * 1959-06-18 1961-03-14 Parke Davis & Co Organic amine compounds and method of obtaining the same
FR1516776A (fr) * 1966-07-21 1968-03-15 Rhone Poulenc Sa Nouveaux dérivés du pyrrole et leur préparation
US3635982A (en) * 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
US3644398A (en) * 1969-04-11 1972-02-22 Robins Co Inc A H 1-carbamoyl-3-phenylpyrrolidines
GB1350582A (en) * 1970-07-24 1974-04-18 Ucb Sa Cerivatives of 2-pyrrolidinone
US3956314A (en) * 1970-07-24 1976-05-11 U.C.B., Societe Anonyme Derivatives of 2-pyrrolidinone
JPS5232064B2 (enExample) * 1972-06-14 1977-08-19
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone

Also Published As

Publication number Publication date
SE407799B (sv) 1979-04-23
JPS612660B2 (enExample) 1986-01-27
AT349459B (de) 1979-04-10
ATA690776A (de) 1978-09-15
CS225802B2 (en) 1984-02-13
NL7610300A (nl) 1977-03-22
SU795465A3 (ru) 1981-01-07
IE43723B1 (en) 1981-05-06
SE7610275L (sv) 1977-03-19
DE2541855A1 (de) 1977-03-31
DK408676A (da) 1977-03-19
GB1563398A (en) 1980-03-26
CH623571A5 (enExample) 1981-06-15
ES451518A2 (es) 1977-10-01
FR2324299B2 (enExample) 1980-02-01
FR2324299A2 (fr) 1977-04-15
CA1077496A (en) 1980-05-13
HU173117B (hu) 1979-02-28
IE43723L (en) 1977-03-18
US4153713A (en) 1979-05-08
DD126894A6 (enExample) 1977-08-17
DK157919C (da) 1990-08-06
DK157919B (da) 1990-03-05
BE846335R (fr) 1977-03-17

Similar Documents

Publication Publication Date Title
JPS5236659A (en) Racemic and optically active 44*polyalkoxyyphenyl** 22pyrrolidone and neuralgia and mental disease treating agent containing same
ZA791728B (en) Cerebral therapeutic agent and its use
GB2013495A (en) Therapeutic method for the treatment of hyperlipodaemias and hyperlipoproteinaemias
IL60890A0 (en) Preparations for the treatment of theileriosic containing piperidyl acetonyl-quinazolinone deravatives and some new such compounds
ZA783464B (en) Dihydropyridazones,their manufacture,and therapeutic agents containing dihydropyridazones
CS188293B2 (en) Fungicide agent and method of preparition of active substances
DZ206A1 (fr) Dérivés de l'indante et médicament qui en contiennent.
GR63669B (en) Process of dose reduction of one biological drastic substance although conserve the biological influenier
JPS5212131A (en) Substituted thiourea and miticide
JPS54130540A (en) Novel nitrile compound and use for perfume drug
GB1541784A (en) Treatment of waste-containing liquor
JPS52151730A (en) Medical composition for treating and preventing relapsic thrombus
JPS5432467A (en) 44hydroxyy22benzimidazolinone derivative * production thereof and pharmaceutical agent containing same for treating or preventing cardiac andcirculatory disease
JPS5448776A (en) 2*44diaminopyrimidine derivative*its manufacture and medicine as active component
JPS5553209A (en) Agricultural drug* its mamufacture and its use
JPS51149276A (en) 22halogenn55trichlormethyll 1*3*44thiadiazole and sterilizer containing same
AT366884B (de) Insektizides und akarizides mittel
JPS533535A (en) Tremor treating agent in parkinsons disease
DE2860033D1 (en) Medicament for the treatment of depressions
JPS5259167A (en) 1*44benzodioxane and medicines for circulatory disease and asthma
JPS5356698A (en) Composition for treating coccidium disease containing 55deazariboflavin and derivative thereof
JPS5214768A (en) 22substitutedd55trifluoromethyll 1*3*44thiadiazole and use of same as pesticide and sterilizer
GB2012260B (en) 4-desacetoxy 4 hydroxyindole dihydroindoles pharmaceutical formulations containing them and their use as antimitotic agents
JPS51128914A (en) Carbamoyloxime* manufacturing process therefor and use as insecticide and miticide
PH14155A (en) Pharmaceutical compositions containing racemic or optically active 1-(2',6'-dimethyl-phenoxy)-2-methylaminopropane and method of use